

BLANK ROME LLP

A Pennsylvania LLP

Stephen M. Orlofsky, Esquire

David C. Kistler, Esquire

Leigh Ann Buziak, Esquire

301 Carnegie Center, 3rd Floor

Princeton, NJ 08540

Telephone: (609) 750-7700

Facsimile: (609) 750-7701

Orlofsky@blankrome.com

Kistler@blankrome.com

LBuziak@blankrome.com

Attorneys for Defendants

MERCHANT & GOULD P.C.

Jeffrey S. Ward (*admitted pro hac vice*)

Wendy M. Ward (*admitted pro hac vice*)

Stephen R. Howe (*admitted pro hac vice*)

Emily M. Wessels (*pro hac vice pending*)

10 E. Doty Street, Suite 600

Madison, WI 53703

Telephone: (608) 280-6751

Facsimile: (612) 332-9081

JWard@MerchantGould.com

WWard@MerchantGould.com

SHowe@MerchantGould.com

EWessels@MerchantGould.com

Attorneys for Defendants

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

PAR PHARMACEUTICAL, INC., and
PAR STERILE PRODUCTS, LLC,

Plaintiffs,

v.

QUVA PHARMA, INC., STUART
HINCHEN, PETER JENKINS, and MIKE
RUTKOWSKI,

Defendants.

Civil Action No. 3:17-cv-06115-
BRM-DEA

Filed Electronically

HIGHLY CONFIDENTIAL

**DECLARATION OF STEPHEN R. HOWE IN SUPPORT OF
DEFENDANTS' OPPOSITION TO PLAINTIFFS' MOTION FOR
PRELIMINARY INJUNCTION**

I, Stephen R. Howe, Esq., declare as follows:

1. I am an attorney-at-law and associate at the law firm Merchant & Gould, P.C.

2. I am admitted to practice in the states of Illinois and Wisconsin.

3. I am making this declaration in support of QuVa's Opposition To Plaintiffs' Motion For Preliminary Injunction.

4. Due to the large number of exhibits relating to the present motion and for the ease of the Court, I submit with this declaration a list of exhibits submitted by Defendants with their opposition papers attached hereto as Exhibit A.

5. For the ease of the Court and to minimize confusion, Defendants have used sequential numbering and started numbering their exhibits with number 205. Plaintiffs used exhibit numbers 1 through 204 with their moving papers.

6. [REDACTED]

[REDACTED]

[REDACTED]

7. [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

8. [REDACTED]

9. [REDACTED]

10. [REDACTED]

11. Attached hereto as Exhibit 210 is a true and correct copy of US Patent Application Publication 2017/0290881 A1 (Kannan Depo. Ex. 13) as produced as QuVa007902-QuVa008055.

12. Attached hereto as Exhibit 211 is a true and correct copy of the CV of John B. White, as produced as QuVa007697-QuVa007701.

13. Attached hereto as Exhibit 212 is a true and correct copy of the Declaration of Stuart Hinchin in Support of Defendants' Opposition to Par's Motion for Expedited Discovery dated September 6, 2017, Court docket entry 023-24.

14. Attached hereto as Exhibit 213 is a true and correct copy of the Declaration of Harold Patterson in support of Defendants' Opposition to Par's Motion for Expedited Discovery with exhibits dated September 6, 2017, Court dock entry 023-4.

15. Attached hereto as Exhibit 214 is a true and correct copy of the Chen email chain with Short et al. dated January 25, 2017, as produced as QuVa002112 – QuVa002133.

16. Attached hereto as Exhibit 215 is a true and correct copy of the Hinchin email chain with Pera dated February 20, 2017, as produced as QuVa003556 – QuVa003357.

17. Attached hereto as Exhibit 216 is a true and correct copy of the Jenkins email chain with Cornelius dated April 25, 2017, as produced as QuVa003204 – QuVa003205.

18. Attached hereto as Exhibit 217 is a true and correct copy of QuVa's supplemental response to Interrogatory 1 (verified) dated October 24, 2017.

19. Attached hereto as Exhibit 218 is a true and correct copy of the transcript of deposition of Stuart Hinchin taken November 10, 2017.

20. Attached hereto as Exhibit 219 is a true and correct copy of U.S. Patent 9,375,478 to Kenney et al., as produced as QuVa007870-QuVa007901.

21. Attached hereto as Exhibit 220 is a true and correct copy of the document titled [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED], as produced by Par as Par-0014835 – Par-0014862.

22. Attached hereto as Exhibit 221 is a true and correct copy of the transcript of deposition of Vinayagam Kannan taken November 7, 2017.

23. Attached hereto as Exhibit 222 is a true and correct copy of the transcript of deposition of Jason Crist taken November 3, 2017.

24. Attached hereto as Exhibit 223 is a true and correct copy of QuVa Lab Notebook pages (Leeah Depo. Ex. 90) as produced as QuVa005033–QuVa005038.

25. Attached hereto as Exhibit 224 is a true and correct copy of the transcript of deposition of Travis Leeah taken November 10, 2017.

26. Attached hereto as Exhibit 225 is a true and correct copy of Popenoe et al., “Degradative Studies on Vasopressin and Performic Acid-Oxidized Vasopressin”, J. Biol. Chem. 205:133-143 (1953), as produced as QuVa007685–QuVa007696.

27. [REDACTED]

28. [REDACTED]

29. Attached hereto as Exhibit 228 is a true and correct copy of the letter from Travis Leeah to the FDA dated April 19, 2017, as produced as QuVa007770-QuVa007772.

30. Attached hereto as Exhibit 229 is a true and correct copy of the resume of Travis Leeah, as produced as QuVa007773- QuVa007775.

31. Attached hereto as Exhibit 230 is a true and correct copy of the document titled Exit Interview, (Crist Depo. Ex. 37) dated May 5, 2017, as produced by Par as Par-0002050-Par-0002051.

32. Attached hereto as Exhibit 231 is a true and correct copy of the Kennedy email to Ashley Short dated February 2, 2017, as produced by Par as Par-0039147-Par-0039148.

33. Attached hereto as Exhibit 232 is a true and correct copy of the Moon email re: Candidate Interview – Ashley Short (Senior Analytical Chemist), dated April 7, 2017, as produced as QuVa005135-QuVa005136.

34. Attached hereto as Exhibit 233 is a true and correct copy of David Short email chain re: Resume – Ashley Short, dated March 26, 2017, as produced as QuVa005144-QuVa005146.

35. Attached hereto as Exhibit 234 is a true and correct copy of Ashley Short's resume, as produced as QuVa005230-QuVa005231.

36. Attached hereto as Exhibit 235 is a true and correct copy of the document titled "Exit Interview," (Crist Depo. Ex. 36) dated June 27, 2017, as produced by Par as Par-0002048-Par-0002049.

37. Attached hereto as Exhibit 236 is a true and correct copy of the Careers@QuVa email to D. Short dated January 7, 2016, as produced as QuVa005182.

38. Attached hereto as Exhibit 237 is a true and correct copy of Chinnasamy Subramaniam's resume, as produced as QuVa005315- QuVa005317.

39. Attached hereto as Exhibit 238 is a timeline titled "No Contact with Par Employees Was Initiated by QuVa."

40. Attached hereto as Exhibit 239 is a true and correct copy of the letter from Carolyn Kaminski to Mr. Subramaniam dated February 25, 2016, as produced as QuVa006254.

41. Attached hereto as Exhibit 240 is a true and correct copy of the letter from QuVa to Chinnasamy Subramaniam, dated January 28, 2016, as produced as QuVa006255-QuVa006257.

42. Attached hereto as Exhibit 241 is a true and correct copy of the document titled "Exit Interview" (Crist Depo. Ex. 33), dated March 11, 2016, as produced by Par as Par-0002056-Par-0002057.

43. Attached hereto as Exhibit 242 is a true and correct copy of David Michael (Mike) Hartley's resume, as produced as QuVa005248-QuVa005251.

44. Attached hereto as Exhibit 243 is a true and correct copy of the document titled QuVa Pharma, Inc. Employment Application, dated February 1, 2016, as produced as QuVa005318-QuVa005319.

45. Attached hereto as Exhibit 244 is a true and correct copy of the letter from QuVa to David Hartley dated February 3, 2016, as produced as QuVa005660-QuVa005662.

46. Attached hereto as Exhibit 245 is a true and correct copy of the document titled "Exit Interview" (Crist Depo. Ex. 31) dated February 12, 2016, as produced by Par as Par-0002052-Par-0002053.

47. Attached hereto as Exhibit 246 is a true and correct copy of a letter from Travis McGrady to Rick Zuehlk, dated February 1, 2016, as produced by Par as Par-0002810.

48. Attached hereto as Exhibit 247 is a true and correct copy of a document titled “2015 Mid Year Performance Appraisal,” listing Travis McGrady, as produced by Par as Par-0003438-Par-0003440.

49. Attached hereto as Exhibit 248 is a true and correct copy of the resume of Travis McGrady, as produced as QuVa005240-QuVa005242.

50. Attached hereto as Exhibit 249 is a true and correct copy of the document titled QuVa Pharma, Inc. Employment Application, dated January 20, 2016, as produced as QuVa005320-QuVa005321.

51. Attached hereto as Exhibit 250 is a true and correct copy of the McGrady email to Rhoades dated December 17, 2015, as produced as QuVa006390.

52. Attached hereto as Exhibit 251 is a true and correct copy of the letter from QuVa to Travis McGrady, dated January 22, 2016, as produced as QuVa007644-QuVa007646.

53. Attached hereto as Exhibit 252 is a true and correct copy of the document titled “Qualitest Pharmaceuticals – Exit Interview Questionnaire” as produced by Par as Par-0038850-Par-0038853.

54. Attached hereto as Exhibit 253 is a true and correct copy of the Fillarini email to Soliman dated April 4, 2017, as produced as QuVa005775.

55. Attached hereto as Exhibit 254 is a true and correct copy of the letter from QuVa to Ahmed Soliman, dated April 21, 2016, as produced as QuVa005900-QuVa005902.

56. Attached hereto as Exhibit 255 is a true and correct copy of the resume of Ahmed Soliman resume, as produced as QuVa006753-QuVa006755.

57. Attached hereto as Exhibit 256 is a true and correct copy of the document titled "Exit Interview" (Crist Depo Ex. 35) dated October 14, 2016, as produced by Par as Par-0002054-Par-0002055.

58. Attached hereto as Exhibit 257 is a true and correct copy of the resume of Guy Thompson, as produced as QuVa005244.

59. Attached hereto as Exhibit 258 is a true and correct copy of the email chain between Careers@QuVa and David Short dated January 21, 2016, as produced as QuVa006029.

60. Attached hereto as Exhibit 259 is a true and correct copy of the November 1, 2016 letter from Guy Thompson to QuVa, as produced as QuVa007588-QuVa007592.

61. Attached hereto as Exhibit 260 is a true and correct copy of the QuVa employment offer to Guy Thompson, as produced as QuVa007595-QuVa007597.

62. Attached hereto as Exhibit 261 is a true and correct copy of the resume of Donna Kohut, as produced as QuVa007679-QuVa007682.

63. Attached hereto as Exhibit 262 is a true and correct copy of the letter from QuVa to Donna Kohut, dated August 28, 2015, as produced as QuVa007579-QuVa007581.

64. Attached hereto as Exhibit 263 is a true and correct copy of resume of Mike Rutkowski, as produced as QuVa006386-QuVa006490.

65. Attached hereto as Exhibit 264 is a true and correct copy of the document titled “A history of the OOS problem”, BioPharm International, as produced as RutkowskiHardDrive-1-0000001-003.

66. Attached hereto as Exhibit 265 is a true and correct copy of the document titled “Position Paper: Segregation of Production Activities for Human and Animal Health Products”, as produced as Rutkowski HardDrive-1-0000004-008.

67. Attached hereto as Exhibit 266 is a true and correct copy of the Braun internal memorandum from Gall re B. the solution, dated January 16, 2014, as produced as Rutkowski HardDrive-1-0000009-012.

68. Attached hereto as Exhibit 267 is a true and correct copy of the April 3, 2017 letter from Mike Rutkowski, as produced as Rutkowski HardDrive-1-0000013.

69. Attached hereto as Exhibit 268 is a true and correct copy of a letter from Mike Rutkowski to Rochester employees, as produced as RutkowskiHardDrive-1-0000014.

70. Attached hereto as Exhibit 269 is a true and correct copy the document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000015-018.

71. Attached hereto as Exhibit 270 is a true and correct copy of the document titled [REDACTED]
[REDACTED], as produced as Rutkowski HardDrive-1-0000019-021.

72. Attached hereto as Exhibit 271 is a true and correct copy of a document titled [REDACTED] as produced as Rutkowski HardDrive-1-0000022-023.

73. Attached hereto as Exhibit 272 is a true and correct copy of the document titled [REDACTED], as produced as Rutkowski HardDrive-1-000024.

74. Attached hereto as Exhibit 273 is a true and correct copy of a letter from Mike Rutkowski letter, as produced as Rutkowski HardDrive-1-0000025.

75. Attached hereto as Exhibit 274 is a true and correct copy of a document with file name ISO 8 clean room areas cleaning sanitization, as produced as Rutkowski HardDrive-1-0000026-037.

76. Attached hereto as Exhibit 275 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000038-043.

77. Attached hereto as Exhibit 276 is a true and correct copy of a document titled [REDACTED]
[REDACTED], as produced as Rutkowski HardDrive-1-0000044-045.

78. Attached hereto as Exhibit 277 is a true and correct copy of a letter from Mike Rutkowski, as produced as Rutkowski HardDrive-1-0000046.

79. Attached hereto as Exhibit 278 is a true and correct copy of a letter from Mike Rutkowski to The Rock dated March 30, 2017, as produced as Rutkowski HardDrive-1-0000047.

80. Attached hereto as Exhibit 279 is a true and correct copy of a letter from Mike Rutkowski to Terry Coughlin, dated March 28, 2017, as produced as Rutkowski HardDrive-1-0000048.

81. Attached hereto as Exhibit 280 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000049-051.

82. Attached hereto as Exhibit 281 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000052-054.

83. Attached hereto as Exhibit 282 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000055.

84. Attached hereto as Exhibit 283 is a true and correct copy of a letter from Mike Rutkowski to Marian Gustafson, as produced as Rutkowski HardDrive-1-0000056.

85. Attached hereto as Exhibit 284 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000057-058.

86. Attached hereto as Exhibit 285 is a true and correct copy of a document titled WG Henschen Job Description: Operations Manager, as produced as Rutkowski HardDrive-1-0000059-060.

87. Attached hereto as Exhibit 286 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000061-064.

88. Attached hereto as Exhibit 287 is a true and correct copy of a document titled [REDACTED]
[REDACTED], as produced as Rutkowski HardDrive-1-0000065-068.

89. Attached hereto as Exhibit 288 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000069-072.

90. Attached hereto as Exhibit 289 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000073-075.

91. Attached hereto as Exhibit 290 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000076-078.

92. Attached hereto as Exhibit 291 is a true and correct copy of an excel sheet with the file name [REDACTED], as produced as Rutkowski HardDrive-1-0000079.

93. Attached hereto as Exhibit 292 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000080.

94. Attached hereto as Exhibit 293 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000081-083.

95. Attached hereto as Exhibit 294 is a true and correct copy of a PowerPoint presentation titled [REDACTED], as produced as RutkowskiHardDrive-1-0000084-089.

96. Attached hereto as Exhibit 295 is a true and correct copy of a document titled [REDACTED], as produced as Rutkowski HardDrive-1-0000090-093.

97. Attached hereto as Exhibit 296 is a true and correct copy of a photograph of the cover of the COW book. The entire book is provided as QuVa004484-4944.

98. Attached hereto as Exhibit 297 is a true and correct copy of FDA's Quality Metrics Report Program: Submission of Quality Metrics Data, as produced as QuVa007683-QuVa007684.

99. Attached hereto as Exhibit 298 is a true and correct copy of the transcript of Rutkowski deposition taken October 27, 2017.

100. Attached hereto as Exhibit 299 is a true and correct copy of the Hinchon email chain with Rhoades dated August 17, 2015, as produced as QuVa006479-QuVa006480.

101. Attached hereto as Exhibit 300 is a true and correct copy of the David Short email chain with Hinchon dated September 4, 2015, as produced as QuVa006636-QuVa006637.

102. Attached hereto as Exhibit 301 is a true and correct copy of the Kohut email chain with Kaminsky dated January 11, 2016, as produced as QuVa006688.

103. Attached hereto as Exhibit 302 is a true and correct copy of the Chinnasamy email to Careers at QuVa dated January 06, 2016, as produced as QuVa006689.

104. Attached hereto as Exhibit 303 is a true and correct copy of the Kaminsky email chain with David Short dated March 9, 2016, as produced as QuVa006751-QuVa006752.

105. Attached hereto as Exhibit 304 is a true and correct copy of David Short's Resume, as produced as QuVa007675-QuVa007678.

106. Attached hereto as Exhibit 305 is a true and correct copy of Stephen J. Rhoades' Resume, as produced as QuVa007776-QuVa007778.

107. Attached hereto as Exhibit 306 is a true and correct copy of Technical Report No. 13 (Revised) Fundamentals of an Environmental Monitoring Program, PDA 2014, as produced as QuVa007831-QuVa007869.

108. Attached hereto as Exhibit 307 is a true and correct copy of Technical Report No. 22 (Revised 2011) Process Simulation for Aseptically Filled Products, PDA 2011, as produced as QuVa007781-QuVa007830.

109. Attached hereto as Exhibit 308 is a true and correct copy of a document titled Proprietary Information and Nondisclosure Agreement, as produced as QuVa007779-QuVa007780.

110. Attached hereto as Exhibit 309 is a true and correct copy of USP 1790, Visual Inspection of Injections, First Supplement to USP 40-NF 35, pp. 8099-8119 dated December 1, 2017, as produced as QuVa008214- QuVa008234.

111. Attached hereto as Exhibit 310 is a true and correct copy of Technical Report No. 36, Current Practices in the Validation of Aseptic Processing – 2001, PDA Journal of Pharmaceutical Science and Technology, Vol. 56, May-June 2002, dated May 1, 2002, as produced as QuVa008176-QuVa008213.

112. Attached hereto as Exhibit 311 is a true and correct copy of Technical Report No. 20, Report on Survey of Current Industry Gowning Practices, PDA Journal of Pharmaceutical Science and Technology, Sup. Vol. 44, No. S2 (1990) dated January 1, 1990, as produced as QuVa008170-QuVa008175.

113. Attached hereto as Exhibit 312 is a true and correct copy of ISO 13408-1 2008E, Aseptic Processing of Health Care Products, Part 1: General Requirements dated June 15, 2008, as produced as QuVa008068-QuVa008121.

114. Attached hereto as Exhibit 313 is a true and correct copy of USP 38 (797) Pharmaceutical Compounding – Sterile Preparations dated December 1, 2015, as produced as QuVa008235-QuVa008279

115. Attached hereto as Exhibit 314 is a true and correct copy of Schwartz, “UPLC™: An Introduction and Review”, Journal of Liquid Chromatography and Related Technologies, 28:1252-1263 (2005), as produced as QuVa008159-QuVa008169.

116. Attached hereto as Exhibit 315 is a chart comparing QuVa 503B compounding with Par traditional sterile manufacturing.

117. Attached hereto as Exhibit 316 is a true and correct copy of Nema et al., “Excipients and Their Use in Injectable Products”, PDA J. Pharm. Sci. and Tech., 51:166-171 (1997), as produced as QuVa008128-QuVa008135.

118. Attached hereto as Exhibit 317 is a true and correct copy of the CV of Rodolfo Pinal, as produced as QuVa008136-QuVa008158.

119. Attached hereto as Exhibit 318 is a true and correct copy of the list of materials considered by Rodolfo Pinal.

120. [REDACTED]

121. [REDACTED]

122. Attached hereto as Exhibit 321 is a true and correct copy of Hyodo, Chapter 6A, Vasopressin (2016), as produced as QuVa008482-QuVa008486.

123. Attached hereto as Exhibit 322 is a true and correct copy of Streitwieser, Heathcock, "Introduction to Organic Chemistry" 2nd Ed., p. 54.

124. Attached hereto as Exhibit 323 is a true and correct copy of the transcript of Peter Jenkins deposition as an individual taken November 9, 2017.

125. Attached hereto as Exhibit 324 is a true and correct copy of the transcript of Peter Jenkins deposition as 30(b)(6) witness taken November 9, 2017.

126. Attached hereto as Exhibit 325 is a true and correct copy of Par's Supplemental Responses to Defendants' First Set of Interrogatories Nos. 10-12 (Crest Depo. Ex. 3) dated October 26, 2017.

127. Attached hereto as Exhibit 326 is a true and correct copy of the document titled "Exit Interview" (Crist Depo. Ex. 27) dated October 23, 2015, as produced by Par as Par-0002058-Par-0002059.

128. Attached hereto as Exhibit 327 is a true and correct copy of the document titled "Exit Interview" (Crist Depo. Ex. 29), as produced by Par as Par-0002060-Par-0002061.

129. Attached hereto as Exhibit 328 is a true and correct copy of Rutkowski email chain with Campanelli (Crist Depo Ex. 39) dated April 10, 2017, as produced by Par as Par-0038733-Par-0038735.

130. Attached hereto as Exhibit 329 is a true and correct copy of the document titled “Mutual Agreement to Arbitrate Claims” dated February 11, 2016, as produced by Par as Par-0001547-Par-0001549.

131. Attached hereto as Exhibit 330 is a true and correct copy of the Kaminsky email chain with Hinchey dated October 12, 2015, as produced as QuVa006510-QuVa006512.

132. Attached hereto as Exhibit 331 is a true and correct copy of the document titled “Recommendation on the Validation of Aseptic Processes” PL 007-6, dated January 1, 2011, as produced as QuVa008487-QuVa008506.

133. Attached hereto as Exhibit 332 is a true and correct copy of White, “Aseptic Process Simulation”, J. Validation Tech (Winter 2010) pp 39-42 dated December 1, 2010, as produced as QuVa008507-QuVa008510.

134. Attached hereto as Exhibit 333 is a true and correct copy of “Media fill simulations”, Focus on Pharma, Manufacturing Chemist, Quality Assurance dated November 2014, as produced as QuVa008479-QuVa008481.

135. Attached hereto as Exhibit 334 is a true and correct copy of the resume of Ludmila Yaheva, as produced as QuVa008511-QuVa008513.

136. Attached hereto as Exhibit 335 is a true and correct copy of the resume of Chen Jianping, as produced as QuVa008514-QuVa008517.

137. Attached hereto as Exhibit 336 is a true and correct copy of the website page titled “Par - People Achieving Results,” found at <https://www.parpharm.com/generics.php>, accessed on December 1, 2017.

138. Attached hereto as Exhibit 337 is a true and correct copy of the document titled “Form S-1 Registration Statement Under the Securities Act of 1933: Par Pharmaceutical Holdings, Inc.”, dated March 12, 2015.

139. Attached hereto as Exhibit 338 is a true and correct copy of the document titled “Endo Completes Acquisition of Par Pharmaceutical and Provides Financial Guidance”, Endo International plc Press Release dated September 28, 2015.

140. Attached hereto as Exhibit 339 is a true and correct copy of the website page titled “Overview,” found at <http://www.endo.com/our-companies/overview>, accessed on November 30, 2017.

141. Attached hereto as Exhibit 340 is a true and correct copy of the website page titled “Careers,” found at <http://www.quvapharma.com/careers/>, accessed on November 30, 2017.

142. Attached hereto as Exhibit 341 is a true and correct copy of the document titled “Center for Drug Evaluation and Research Application Number 204485Orig1s000 Medical Review(s),” dated April 4, 2014.

143. Attached hereto as Exhibit 342 is a true and correct copy of Vasostrict Label, Par Pharmaceutical Companies, Inc., April 17, 2014, as accessed via www.accessdata.fda.gov.

144. Attached hereto as Exhibit 343 is a true and correct copy of the document titled “Some Selected History of Oxytocin and Vasopressin,” The National Institute of Mental Health, accessed through www.nimh.nih.gov on November 30, 2017.

145. Attached hereto as Exhibit 344 is a true and correct copy of the website page “Warner-Lambert & King In \$125M Deal,” The Pharma Letter, April 3, 1998, found at <https://www.thepharmaletter.com/article/warner-lambert-king-in-125m-deal>, accessed on November 30, 2017.

146. Attached hereto as Exhibit 345 is a true and correct copy of the document titled “Form 8-K: King Pharmaceuticals, Inc.,” dated July 19, 2007.

147. Attached hereto as Exhibit 346 is a true and correct copy of the document titled “Vasopressin Injection Drug Shortage Notice,” found at <https://www.drugs.com/drug-shortages/vasopressin-injection-795>, as accessed on November 30, 2017.

148. Attached hereto as Exhibit 347 is a true and correct copy of the document titled “Declaration of Peter Jenkins in Support of Defendants’ Opposition to Par’s Motion for Expedited Discovery,” dated September 5, 2017.

149. Attached hereto as Exhibit 348 is a true and correct copy of the website page titled “What are unapproved drugs and why are they on the market?” found at <https://www.fda.gov/AboutFDA/Transparency/Basics/ucm213030.htm>, as accessed on November 30, 2017.

150. Attached hereto as Exhibit 349 is a true and correct copy of Defendants’ Opposition to Par’s Motion for Expedited Discovery, dated September 7, 2017.

151. Attached hereto as Exhibit 350 is a true and correct copy of the document titled “Guidance for FDA Staff and Industry: Marketed Unapproved Drugs — Compliance Policy Guide,” Center for Drug Evaluation and Research at the FDA, dated September 19, 2011.

152. Attached hereto as Exhibit 351 is a true and correct copy of “Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” Food and Drug Administration, Updated July 1, 2017.

153. Attached hereto as Exhibit 352 is a true and correct copy of the website page titled “Compounding and the FDA: Questions and Answers,” found at <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm339764.htm>, as accessed on November 30, 2017.

154. Attached hereto as Exhibit 353 is a true and correct copy of the Vasostrict Label, Par Pharmaceutical Companies, Inc., December 21, 2016, as accessed via www.accessdata.fda.gov.

155. Attached hereto as Exhibit 354 is a true and correct copy of Roman L. Weil, Daniel G. Lentz, and Elizabeth A. Evans, eds., *Litigation Services Handbook: The Role of the Financial Expert*, Sixth edition, John Wiley and Sons, 2017, Chapter 4: “Damages Theories and Causation Issues” (2017).

156. Attached hereto as Exhibit 355 is a true and correct copy of an image of the Par Pharmaceutical website page “Par Product Summary: Vasostrict,” as accessed via www.parsterileproducts.com/products/products/vasostrict/.

157. Attached hereto as Exhibit 356 is a true and correct copy of a document titled “Update: FDA revises final guidances on interim policy for certain bulk drug substances used in compounding,” as accessed via www.fda.gov/drugs/drugsafety/ucm502075.htm on December 6, 2017.

158. Attached hereto as Exhibit 357 is a true and correct copy of the document titled “”ENDO International PLC: 4Q Wrap-Up: Modest Sales Beat, but Lowering Ests on Pessimistic ‘17 Guide,” Leerink, February 28, 2017, as produced as Par-0040106-Par-0040116

159. Attached hereto as Exhibit 358 is a true and correct copy of the document titled Truven Health Analytics, “AWP Policy,” revised October 1, 2014.

160. Attached hereto as Exhibit 359 is a true and correct copy of the document titled “RED BOOK,” as accessed via www.truvenhealth.com.

161. Attached hereto as Exhibit 360 is a true and correct copy of Michael Hiltzik, “The little-known FDA program that’s driving drug prices higher,” LA Times, September 23, 2015.

162. Attached hereto as Exhibit 361 is a true and correct copy of “Some Drug Price Hikes Due to FDA Safety Program,” News Max, October 7, 2015.

163. Attached hereto as Exhibit 362 is a true and correct copy of the document titled [REDACTED] dated November 8, 2017, as produced by Par as Par-0039612-Par-0039614.

164. Attached hereto as Exhibit 363 is a true and correct copy of the document titled [REDACTED] as produced by Par as Par-0040199.

165. Attached hereto as Exhibit 364 is a true and correct copy of the document titled “ENDO International PLC: Lowering Ests, Persistent US Gx Headwinds, Lowering PT to \$12,” Leerink Partners dated January 24, 2017, as produced by Par as Par-0040117-Par-0040127.

166. Attached hereto as Exhibit 365 is a true and correct copy of the document titled “Form 10-K: Endo International Plc” for fiscal year ended December 31, 2015.

167. Attached hereto as Exhibit 366 is a true and correct copy of the document titled “Form 10-K: Endo International Plc” for fiscal year ended December 31, 2016.

168. Attached hereto as Exhibit 367 is a true and correct copy of the document titled “Form 10-Q: Endo International Plc” for quarterly period ended September 30, 2017.

169. Attached hereto as Exhibit 368 is a true and correct copy of the document titled “Par Sterile Products – Products Database,” as produced by Par as Par-0040158-Par-0040161.

170. Attached hereto as Exhibit 369 is a true and correct copy of the Par Pharmaceutical – Product Catalog, as accessed at www.parpharm.com/product-catalog.php on December 5, 2017.

171. Attached hereto as Exhibit 370 is a true and correct copy of the document titled “Center for Drug Evaluation and Research Application Number 204485Orig1s000 Summary Review,” dated March 20, 2014.

172. Attached hereto as Exhibit 371 is a true and correct copy of the FDA.gov website page for “Outsourcing Facilities,” as accessed at <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm393571.htm> on November 30, 2017.

173. Attached hereto as Exhibit 372 is a true and correct copy of Jennifer Gudeman, Michael Jozwiakowski, John Chollet, and Michael Randell, “Potential risks of pharmacy compounding,” Drug RD, Vol 13, March 23, 2013

174. Attached hereto as Exhibit 373 is a true and correct copy of “American Regent, Inc. Initiates Voluntary Recall of Seventeen Lots of Vasopressin Injection, USP, Multiple Dose Vials due to Sub-Potency,” PR Newswire, August 3, 2011.

175. Attached hereto as Exhibit 374 is a true and correct copy of a document titled “PHAST Prescription,” Symphony Health.

176. Attached hereto as Exhibit 375 is a true and correct copy of Hoefle, “The Early History of Parke-Davis and Company”, Bulletin for the History of Chemistry 25, No. 1 (2000).

177. Attached hereto as Exhibit 376 is a true and correct copy of the letter from the FDA to Mr. Vasquez re: NDA Approval, dated April 17, 2014.

178. Attached hereto as Exhibit 377 is a true and correct copy of the document titled [REDACTED] as produced by Par as Par-0039661- Par-0039662.

179. Attached hereto as Exhibit 378 is a true and correct copy of the website www.americanregent.com/Our_Company.aspx as accessed on December 4, 2017.

180. Attached hereto as Exhibit 379 is a true and correct copy of the document titled Center for Drug Evaluation and Research Approval Package for Application Number: 204485Orig1s004, dated December 16, 2016.

181. Attached hereto as Exhibit 380 is a true and correct copy of the document titled “How did the Federal Food, Drug, and Cosmetic Act come about?” from www.fda.gov.

182. Attached hereto as Exhibit 381 is a true and correct copy of the document titled Symphony Health Integrated Pharmaceutical Audit Suite data.

183. Attached hereto as Exhibit 382 is a true and correct copy of the Truven Health Analytics website Red Book Online Product Details pages for Pitressin and Vasostrict, as accessed on December 1, 2017.

184. Attached hereto as Exhibit 383 is a true and correct copy of the list of materials considered by Patterson.

185. Attached hereto as Exhibit 384 is a true and correct copy of the CV of Brian T. Wolfinger.

186. Attached hereto as Exhibit 385 is a true and correct copy of the list of materials considered by Brian T. Wolfinger.

187. Attached hereto as Exhibit 386 is a true and correct copy of a chart titled “Thumb Drive Identification Chart.”

188. Attached hereto as Exhibit 387 is a true and correct copy of a series of photographs of the Lenovo drive inspected by Brian T. Wolfinger.

189. Attached hereto as Exhibit 388 is a true and correct copy of the image log for the image provided of Ashley Short's hard drive.

190. Attached hereto as Exhibit 389 is a true and correct copy of the image log for the image provided of Chinnasamay Subramaniam's hard drive.

191. Attached hereto as Exhibit 390 is a true and correct copy of the image log for the image provided of Mike Rutkowski's hard drive.

192. Attached hereto as Exhibit 391 is a true and correct copy of a screenshot provided from the forensic analysis conducted by Brian T. Wolfinger.

193. Attached hereto as Exhibit 392 is a true and correct copy a screenshot provided from the forensic analysis conducted by Brian T. Wolfinger, containing the title "Post Departure Disk Defragmentation: Screenshot of Software Analysis."

194. Attached hereto as Exhibit 393 is a true and correct copy of a PDF printout of the Lenovo Website as accessed on December 5, 017 at: https://pcsupport.lenovo.com/...r900vwzf?linkTrack=Homepage%3ABody_Search+Products&searchType=6&keyWordSearch=R900VWZF

195. Attached hereto as Exhibit 394 is a true and correct copy of a PDF printout of the LaptopMag Website as accessed on December 1, 017 at: <https://www.laptopmag.com/articles/defragment-hard-drive-windows>

196. Attached hereto as Exhibit 395 is a true and correct copy of a document titled “Defrag & Summary Data” prepared by Wolfinger Forensics.

197. Attached hereto as Exhibit 396 is a true and correct copy of a screenshot provided from the forensic analysis conducted by Brian T. Wolfinger, containing the heading: Operating System Install Dates for Rutkowski and Subramaniam.

198. Attached hereto as Exhibit 397 is a true and correct copy of the set documents containing bates numbers Par-0040242 to Par-0040253 as produced by Par in this litigation.

199. Attached hereto as Exhibit 398 is a true and correct copy of a screenshot provided from the forensic analysis conducted by Brian T. Wolfinger.

200. Attached hereto as Exhibit 399 is a true and correct copy of the set of documents containing bates numbers OMM-SC-0000047 – OMM-SC-0000053 as produced by Par in this litigation.

201. Attached hereto as Exhibit 400 is a true and correct copy of the document containing bates number OMM-SC-0000001 as produced by Par in this litigation.

202. Attached hereto as Exhibit 401 is a true and correct copy of Par Supplemental Responses to Interrogatories Nos. 1, 5, 8 and 9 dated October 30, 2017.

203. Attached hereto as Exhibit 402 is a true and correct copy of Bi et al., “HPLC Method for Quantification of Arginine Containing Vasopressin”, J. Liq. Chrom. & Rel. Technol. 22(4):551-560 (1999).

204. Attached hereto as Exhibit 403 is a true and correct copy of Hermann et al., “Urinary excretion of angiotensin I, II, arginine vasopressin and oxytocin in patients with anaphylactoid reactions”, Clinical and Experimental Allergy, 22:845-853 (1992).

205. Attached hereto as Exhibit 404 is a true and correct copy of Tsukakzaki et al, “Development of a High-Sensitivity Quantitation Method for Arginine Vasopressin by High-Performance Liquid Chromatography Tandem Mass Spectrometry, and Comparison with Quantitative Values by Radioimmunoassay”, Analytical Sciences, 32:153-159 (February 2016).

206. Attached hereto as Exhibit 405 is a true and correct copy of Zhang et al. “Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child”, J. Pharm. & Biomedical Analysis, 99:67-73 (2014).

207. Attached hereto as Exhibit 406 is a true and correct copy of the CV of Mohan Rao.

208. Attached hereto as Exhibit 407 is a true and correct copy of the list of materials considered by Mohan Rao.

209. Attached hereto as Exhibit 408 is a true and correct copy of the document titled Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act, Guidance for Industry, January 2017.

210. Attached hereto as Exhibit 409 is a true and correct copy of the transcript of September 29, 2017 hearing on expedited discovery in the instant action.

211. Attached hereto as Exhibit 410 is a true and correct copy of the Declaration of Ahmed Soliman filed concurrently herewith.

212. Attached hereto as Exhibit 411 is a true and correct copy of the Declaration of Angela Palomarez filed concurrently herewith.

213. Attached hereto as Exhibit 412 is a true and correct copy of the Declaration of Ashley Short filed concurrently herewith.

214. Attached hereto as Exhibit 413 is a true and correct copy of the Declaration of Chinnasamy Subramaniam filed concurrently herewith.

215. Attached hereto as Exhibit 414 is a true and correct copy of the Declaration of David Michael Hartley filed concurrently herewith.

216. Attached hereto as Exhibit 415 is a true and correct copy of the Declaration of David Short filed concurrently herewith.

217. Attached hereto as Exhibit 416 is a true and correct copy of the Declaration of Donna Kohut filed concurrently herewith.

218. Attached hereto as Exhibit 417 is a true and correct copy of the Declaration of Guy Thompson filed concurrently herewith.

219. Attached hereto as Exhibit 418 is a true and correct copy of the Declaration of John B. White filed concurrently herewith.

220. Attached hereto as Exhibit 419 is a true and correct copy of the Declaration of Mike Rutkowski filed concurrently herewith.

221. Attached hereto as Exhibit 420 is a true and correct copy of the Declaration of Stephen Rhoades filed concurrently herewith.

222. Attached hereto as Exhibit 421 is a true and correct copy of the Declaration of Stuart Hinchin filed concurrently herewith.

223. Attached hereto as Exhibit 422 is a true and correct copy of the Declaration of Travis Leeah filed concurrently herewith.

224. Attached hereto as Exhibit 423 is a true and correct copy of the Declaration of Travis McGrady filed concurrently herewith.


225. Attached hereto as Exhibit 424 is a true and correct copy of the Declaration of Harold Patterson filed concurrently herewith.

226. Attached hereto as Exhibit 425 is a true and correct copy of the Declaration of Dr. Rodolfo Pinal filed concurrently herewith.

227. Attached hereto as Exhibit 426 is a true and correct copy of the Declaration of Brian T. Wolfinger filed concurrently herewith.

228. Attached hereto as Exhibit 427 is a true and correct copy of the Declaration of Dr. Mohan P. Rao filed concurrently herewith.

I declare under penalty of perjury that the foregoing is true and correct.
Executed on December 8, 2017.



Stephen R. Howe, Esq.

EXHIBIT A

LIST OF DEFENDANTS' EXHIBITS SUBMITTED WITH OPPOSITION TO PLAINTIFFS' MOTION FOR PRELIMINARY INJUNCTION

EXHIBIT NOS. 205 – 427

| EX NO. | DESCRIPTION | DATE | BATES |
|--------|--|------------|----------------------------|
| 205 | [REDACTED] | 03-31-2016 | QuVa007662- QuVa007674 |
| 206 | [REDACTED] | 08-01-2017 | QuVa007650- QuVa007661 |
| 207 | [REDACTED] | 05-02-2014 | QuVa007763- QuVa007769 |
| 208 | [REDACTED] | 12-02-2015 | QuVa007702- QuVa007754 |
| 209 | [REDACTED] | 11-28-2017 | QuVa007755- QuVa007762 |
| 210 | US Patent Application Publication 2017/0290881 A1 (Kannan Depo. Ex. 13) | 10-12-2017 | QuVa007902- QuVa008055 |
| 211 | CV of John B. White | | QuVa007697- QuVa007701 |
| 212 | Declaration of Stuart Hinchin in Support of Defendants' Opposition to Par's Motion for Expedited Discovery, DI 023-4. | 09-06-2017 | |
| 213 | Declaration of Harold Patterson in support of Defendants' Opposition to Par's Motion for Expedited Discovery with exhibits, DID 023-4. | 09-06-2017 | |
| 214 | Chen email chain with Short et al | 01-25-2017 | QuVa002112 – QuVa002133 |
| 215 | Hinchin email chain with Pera | 02-20-2017 | QuVa003556 – QuVa003357 |
| 216 | Jenkins email chain with Cornelius | 04-25-2017 | QuVa003204- QuVa003205 |
| 217 | QuVa Supplemental Response to Interrogatory 1 (verified) | 10-24-2017 | |

| | | | |
|-----|---|------------|---------------------------|
| 218 | Transcript of deposition of Stuart Hinch | 11-10-2017 | |
| 219 | U. S. Patent 9,375,478 Kenney et al. | 06-28-2016 | QuVa007870- QuVa007901 |
| 220 | [REDACTED] | 11-24-2015 | Par-0014835-Par-0014862 |
| 221 | Transcript of deposition of Vinayagam Kannan | 11-07-2017 | |
| 222 | Transcript of deposition of Jason Crist | 11-03-2017 | |
| 223 | QuVa Lab Notebook pages (Leeah Depo. Ex. 90) | 10-17-2017 | QuVa005033- QuVa005038 |
| 224 | Transcript of deposition of Travis Leeah | 11-10-2017 | |
| 225 | Popenoe et al., "Degradative Studies on Vasopressin and Performic Acid-Oxidized Vasopressin", J. Biol. Chem. 205:133-143 (1953) | 06-15-1953 | QuVa007685- QuVa007696 |
| 226 | [REDACTED] | | QuVa008062- QuVa008067 |
| 227 | [REDACTED] | | QuVa008056- QuVa008061 |
| 228 | QuVa Letter to FDA nominating Vasopressin for bulk drug substance | 04-19-2017 | QuVa007770- QuVa007772 |
| 229 | Resume of Travis Leeah | | QuVa007773- QuVa007775 |
| 230 | Par exit interview with Ashley Short (Crist Depo. Ex. 37) | 05-05-2017 | Par-0002050-Par-0002051 |
| 231 | Kennedy email to Ashley Short | 02-02-2017 | Par-0039147-Par-0039148 |
| 232 | Moon email re Ashley Short interview schedule | 04-07-2017 | QuVa005135- QuVa005136 |
| 233 | David Short email chain regarding Ashley Short | 03-26-2017 | QuVa005144- QuVa005146 |
| 234 | Ashley Short resume | | QuVa005230- QuVa005231 |
| 235 | Par exit interview with Chinnasamy Subramaniam (Crist Depo. Ex. 36) | 06-27-2017 | Par-0002048-Par-0002049 |
| 236 | Careers@QuVa email to D. Short re Chinnasamy Subramaniam resume | 01-07-2016 | QuVa005182 |
| 237 | Chinnasamy Subramaniam resume | | QuVa005315- QuVa005317 |
| 238 | Timeline titled "No Contact with Par Employees Was Initiated by QuVa." | | |
| 239 | QuVa letter to Subramaniam rescinding employment offer | 02-25-2016 | QuVa006254 |

| | | | |
|-----|---|------------|-----------------------------|
| 240 | QuVa employment offer to Chinnasamy Subramaniam | 01-28-2016 | QuVa006255- QuVa006257 |
| 241 | Par exit interview with Hartley (Crist Depo. Ex. 33) | 03-11-2016 | Par-0002056-Par-0002057 |
| 242 | David Michael (Mike) Hartley resume | | QuVa005248- QuVa005251 |
| 243 | Hartley employment application with QuVa | 02-01-2016 | QuVa005318- QuVa005319 |
| 244 | QuVa employment offer to Hartley | 02-03-2016 | QuVa005660- QuVa005662 |
| 245 | Par exit interview with Travis McGrady (Crist Depo. Ex. 31) | 02-12-2016 | Par-0002052-Par-0002053 |
| 246 | McGrady resignation letter to Par | 02-01-2016 | Par-0002810 |
| 247 | McGrady 2015 Mid-Year Performance Appraisal | 07-10-2015 | Par-0003438-Par-0003440 |
| 248 | McGrady resume | | QuVa005240- QuVa005242 |
| 249 | McGrady employment application with QuVa | 01-20-2016 | QuVa005320- QuVa005321 |
| 250 | McGrady email to Rhoades | 12-17-2015 | QuVa006390 |
| 251 | QuVa employment offer to McGrady | 01-22-2016 | QuVa007644- QuVa007646 |
| 252 | Qualitest Pharmaceuticals exit interview questionnaire by Soliman | 12-03-2015 | Par-0038850-Par-0038853 |
| 253 | Fillarini email to Soliman re Ashley Short | 04-04-2017 | QuVa005775 |
| 254 | QuVa employment offer to Soliman | 04-21-2016 | QuVa005900- QuVa005902 |
| 255 | Soliman resume | | QuVa006753- QuVa006755 |
| 256 | Par exit interview with Thompson (Crist Depo Ex. 35) | 10-14-2016 | Par-0002054- Par-0002055 |
| 257 | Thompson resume | | QuVa005244 |
| 258 | Careers@QuVa email chain re Thompson resume | 01-21-2016 | QuVa006029 |
| 259 | Thompson employment application with QuVa | 10-26-2016 | QuVa007588- QuVa007592 |
| 260 | QuVa employment offer to Thompson | 11-01-2016 | QuVa007595- QuVa007597 |
| 261 | Kohut resume | | QuVa007679- QuVa007682 |
| 262 | QuVa employment offer to Kohut | 08-28-2015 | QuVa007579- QuVa007581 |
| 263 | Rutkowski resume | | QuVa006386- QuVa006490 |

| | | | |
|-----|---|------------|--------------------------------------|
| 264 | A history of the OOS problem, BioPharm International | | Rutkowski HardDrive-1-0000001-003 |
| 265 | Position Paper: Segregation of Production Activities for Human and Animal Health Products | | Rutkowski HardDrive-1-0000004-008 |
| 266 | Braun internal memorandum from Gall re B. The Solution | 01-16-2014 | Rutkowski HardDrive-1-0000009-012 |
| 267 | Par letter of recommendation for Dajour Simpson | 04-03-2017 | Rutkowski HardDrive-1-0000013 |
| 268 | Rutkowski letter to Rochester employees | 12-31-2013 | Rutkowski HardDrive-1-0000014 |
| 269 | [REDACTED] | | Rutkowski HardDrive-1-0000015-018 |
| 270 | [REDACTED] | | Rutkowski HardDrive-1-0000019-021 |
| 271 | [REDACTED] | 05-04-2016 | Rutkowski HardDrive-1-0000022-023 |
| 272 | Group Leader, roles and responsibilities | | Rutkowski HardDrive-1-0000024 |
| 273 | Rutkowski letter of recommendation for DeAnn Johnson | | Rutkowski HardDrive-1-0000025 |
| 274 | ISO 8 clean room areas cleaning sanitization | | Rutkowski HardDrive-1-0000026-037 |
| 275 | [REDACTED] | | Rutkowski HardDrive-1-0000038-043 |
| 276 | [REDACTED] | | Rutkowski HardDrive-1-0000044-045 |
| 277 | Rutkowski letter of recommendation for Dajour Simpson | | Rutkowski HardDrive-1-0000046 |
| 278 | Rutkowski letter to The Rock | 03-30-2017 | Rutkowski HardDrive-1-0000047 |
| 279 | Rutkowski resignation letter | 03-28-2017 | Rutkowski HardDrive-1-0000048 |
| 280 | [REDACTED] | | Rutkowski HardDrive-1-0000049-051 |
| 281 | [REDACTED] | | Rutkowski HardDrive-1-0000052-054 |
| 282 | Par Rochester Site Manifesto | | Rutkowski HardDrive-1-0000055 |
| 283 | Rutkowski letter to Gustafson re common stock | | Rutkowski HardDrive-1-0000056 |

| | | | |
|-----|---|------------|--------------------------------------|
| 284 | [REDACTED] | | Rutkowski HardDrive-1-0000057-058 |
| 285 | WG Henschen job description for Operations Manager | | Rutkowski HardDrive-1-0000059-060 |
| 286 | [REDACTED] | 09/13/2011 | Rutkowski HardDrive-1-0000061-064 |
| 287 | [REDACTED] | | Rutkowski HardDrive-1-0000065-068 |
| 288 | [REDACTED] | | Rutkowski HardDrive-1-0000069-072 |
| 289 | [REDACTED] | | Rutkowski HardDrive-1-0000073-075 |
| 290 | [REDACTED] | | Rutkowski HardDrive-1-0000076-078 |
| 291 | [REDACTED] | | Rutkowski HardDrive-1-0000079 |
| 292 | [REDACTED] | | Rutkowski HardDrive-1-0000080 |
| 293 | [REDACTED] | | Rutkowski HardDrive-1-0000081-083 |
| 294 | [REDACTED] | | Rutkowski HardDrive-1-0000084-089 |
| 295 | [REDACTED] | 08/17/2016 | Rutkowski HardDrive-1-0000090-093 |
| 296 | [REDACTED] | | |
| 297 | FDA's Quality Metrics Report Program: Submission of Quality Metrics Data | | QuVa007683- QuVa007684 |
| 298 | Transcript of Rutkowski deposition | 10-27-2017 | |
| 299 | Hinchen email chain with Rhoades | 08-17-2015 | QuVa006479- QuVa006480 |
| 300 | David Short email chain with Hinchen, re: Hello | 09-04-2015 | QuVa006636- QuVa006637 |
| 301 | Kohut email chain with Kaminsky, re : Employment Letter A Ashford | 01-11-2016 | QuVa006688 |
| 302 | Chinnasamy email to careers at QuVa , re: Resume – Chinnasamy Subramaniam | 01-06-2016 | QuVa006689 |
| 303 | Kaminsky email chain with David Short, re: candidate for Director of Analytical Lab R&D – Ahmed Soliman | 03-09-2016 | QuVa006751- QuVa006752 |

| | | | |
|-----|---|------------|--|
| 304 | David Short Resume | | QuVa007675- QuVa007678 |
| 305 | Stephen J. Rhoades Resume | | QuVa007776- QuVa007778 |
| 306 | Technical Report No. 13 (Revised) Fundamentals of an Environmental Monitoring Program, PDA 2014 | 2014 | QuVa007831- QuVa007869 |
| 307 | Technical Report No. 22 (Revised 2011) Process Simulation for Aseptically Filled Products, PDA 2011 | 2011 | QuVa007781- QuVa007830 |
| 308 | Rutkowski Proprietary Information and Nondisclosure Agreement with Endo | | QuVa007779- QuVa007780 |
| 309 | USP 1790, Visual Inspection of Injections, First Supplement to USP 40-NF 35, pp. 8099-8119 | 12-01-2017 | QuVa008214- QuVa008234 |
| 310 | Technical Report No. 36, Current Practices in the Validation of Aseptic Processing – 2001, PDA Journal of Pharmaceutical Science and Technology, Vol. 56, May-June 2002 | 05-01-2002 | QuVa008176- QuVa008213 |
| 311 | Technical Report No. 20, Report on Survey of Current Industry Gowning Practices, PDA Journal of Pharmaceutical Science and Technology, Sup. Vol. 44, No. S2 (1990) | 01-01-1990 | QuVa008170- QuVa008175 |
| 312 | ISO 13408-1 2008E, Aseptic Processing of Health Care Products, Part 1: General Requirements | 06-15-2008 | QuVa008068- QuVa008121 |
| 313 | USP 38 (797) Pharmaceutical Compounding – Sterile Preparations | 12-1-2015 | QuVa008235- QuVa008279 |
| 314 | Schwartz, “UPLC™: An Introduction and Review”, Journal of Liquid Chromatography and Related Technologies, 28:1252-1263 (2005) | 2005 | QuVa008159- QuVa008169 |
| 315 | Chart comparing QuVa 503B compounding with Par traditional sterile manufacturing | | |
| 316 | Nema et al., “Excipients and Their Use in Injectable Products”, PDA J. Pharm. Sci. and Tech., 51:166-171 (1997) | 1997 | QuVa008128- QuVa008135 |
| 317 | Pinal CV | | QuVa008136- QuVa008158 |
| 318 | List of materials considered by Pinal | | |
| 319 | ██ | 07-31-2015 | QuVa000838- QuVa000839 |
| 320 | ██ | 09-24-2017 | QuVa002110- QuVa002111; QuVa002114- QuVa002133- |
| 321 | Hyodo, Chapter 6A, Vasopressin (2016) | | QuVa008482- QuVa008486 |

| | | | |
|-----|--|------------|---------------------------|
| 322 | Streitwieser, Heathcock, "Introduction to Organic Chemistry" 2nd Ed., p. 54 | | |
| 323 | Transcript of Peter Jenkins deposition as individual | 11-09-2017 | |
| 324 | Transcript of Peter Jenkins deposition as 30(b)(6) witness | 11-09-2017 | |
| 325 | Par's Supplemental Responses to Defendants' First Set of Interrogatories (Crest Depo. Ex. 3) | 10-26-2017 | |
| 326 | Par exit interview with David Short (Crist Depo. Ex. 27) | 10-23-2015 | Par-0002058-Par-0002059 |
| 327 | Par exit interview with Steve Rhoades (Crist Depo. Ex. 29) | 10-16-2015 | Par-0002060-Par-0002061 |
| 328 | Rutkowski email chain with Campaneli (Crist Depo Ex. 39) | 04-10-2017 | Par-0038733-Par-0038735 |
| 329 | Endo and Soliman Mutual Agreement to Arbitrate Claims | 02-11-2016 | Par-0001547-Par-0001549 |
| 330 | Kaminsky email chain with Hinchey re David Short | 10-12-2015 | QuVa006510- QuVa006512 |
| 331 | PIC's Recommendation on the Validation of Aseptic Processes PL 007-6 | 01-01-2011 | QuVa008487- QuVa008506 |
| 332 | White, "Aseptic Process Simulation", J. Validation Tech (Winter 2010) pp 39-42. | 12-01-2010 | QuVa008507- QuVa008510 |
| 333 | "Media fill simulations", Focus on Pharma, Manufacturing Chemist, Quality Assurance | 11-00-2014 | QuVa008479- QuVa008481 |
| 334 | Resume of Ludmila Yaheva | | QuVa008511- QuVa008513 |
| 335 | Resume of Chen Jianping | | QuVa008514- QuVa008517 |
| 336 | "Par - People Achieving Results," <www.parpharm.com> | | |
| 337 | Par Pharmaceutical Holdings, Inc.'s Form S-1, March 12, 2015 | 03-12-2015 | |
| 338 | Endo Completes Acquisition of Par Pharmaceutical and Provides Financial Guidance, Endo International plc Press Release | 09-28-2015 | |
| 339 | "Overview," <www.endo.com> | | |
| 340 | "Careers" <www.quvapharma.com> | | |
| 341 | "Vasotriect Medical Review(s)," Center for Drug Evaluation and Research, April 4, 2014 | 04-04-2014 | |
| 342 | Vasotriect Label, Par Pharmaceutical Companies, Inc., April 17, 2014, accessed via <www.accessdata.fda.gov> | 04-17-2014 | |
| 343 | "Some Selected History of Oxytocin and Vasopressin," The National Institute of Mental Health | | |

| | | | |
|-----|--|------------|-------------------------|
| 344 | Warner-Lambert & King In \$125M Deal,” The Pharma Letter, April 3, 1998 | 04-03-1998 | |
| 345 | King Pharmaceuticals, Inc.’s Form 8-K, July 19, 2007 | 07-19-2007 | |
| 346 | “Vasopressin Injection Drug Shortage Notice,” <www.drugs.com> | | |
| 347 | Declaration of Peter Jenkins, September 5, 2017 | 09-05-2017 | |
| 348 | “What are unapproved drugs and why are they on the market?” <www.fda.gov> | | |
| 349 | Defendants’ Opposition to Par’s Motion for Expedited Discovery | 09-07-2017 | |
| 350 | “Guidance for FDA Staff and Industry: Marketed Unapproved Drugs — Compliance Policy Guide,” Center for Drug Evaluation and Research at the FDA, September 19, 2011 | 09-19-2011 | |
| 351 | “Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” Food and Drug Administration, Updated July 1, 2017 | 07-01-2-17 | |
| 352 | “Compounding and the FDA: Questions and Answers,” <www.fda.gov> | | |
| 353 | Vasostriect Label, Par Pharmaceutical Companies, Inc., December 21, 2016, accessed via <www.accessdata.fda.gov> | 12-21-2016 | |
| 354 | Roman L. Weil, Daniel G. Lentz, and Elizabeth A. Evans, eds., Litigation Services Handbook: The Role of the Financial Expert, Sixth edition, John Wiley and Sons, 2017, Chapter 4: “Damages Theories and Causation Issues” | 2017 | |
| 355 | Par Sterile Products website, Par Product Summary: Vasostriect,” <www.parsterileproducts.com> | | |
| 356 | Update: FDA revises final guidances on interim policy for certain bulk drug substances used in compounding,” <www.fda.gov> | | |
| 357 | 4Q Wrap-Up: Modest Sales Beat, but Lowering Ests on Pessimistic ‘17 Guide,” Leerink, February 28, 2017 | 02-28-2017 | Par-0040106-Par-0040116 |
| 358 | Truven Health Analytics, “AWP Policy,” Revised October 1, 2014 | 10-01-2014 | |
| 359 | Truven Health Analytics website, “RED BOOK,” <www.truvenhealth.com> | | |
| 360 | Michael Hiltzik, “The little-known FDA program that’s driving drug prices higher,” LA Times, September 23, 2015 | 09-23-2015 | |
| 361 | “Some Drug Price Hikes Due to FDA Safety Program,” News Max, October 7, 2015 | 10-07-2015 | |
| 362 | ██████████ | 11-08-2017 | Par-0039612-Par-0039614 |

| | | | |
|-----|--|------------|-------------------------|
| 363 | | | Par-0040199 |
| 364 | "Lowering Ests, Persistent US Gx Headwinds, Lowering PT to \$12," Leerink Partners | 01-24-2017 | Par-0040117-Par-0040127 |
| 365 | Endo International Plc's 10-K for fiscal year ended December 31, 2015 | 12-31-2015 | |
| 366 | Endo International Plc's 10-K for fiscal year ended December 31, 2016 | 12-31-2016 | |
| 367 | Endo International plc's 10-Q for quarterly period ended September 30, 2017 | 09-30-2017 | |
| 368 | Par Sterile Products – Products Database | | Par-0040158-Par-0040161 |
| 369 | Par Pharmaceutical – Product Catalog, <www.parpharm.com> | | |
| 370 | "Vasostriect Summary Review," Center for Drug Evaluation and Research, Application Number 204485Orig1s000, March 20, 2014 | 03-20-2014 | |
| 371 | "Outsourcing Facilities," <www.fda.gov> | | |
| 372 | Jennifer Gudeman, Michael Jozwiakowski, John Chollet, and Michael Randell, "Potential risks of pharmacy compounding," Drug RD, Vol 13, March 23, 2013 | 03-23-2013 | |
| 373 | American Regent, Inc. Initiates Voluntary Recall of Seventeen Lots of Vasopressin Injection, USP, Multiple Dose Vials due to Sub-Potency," PR Newswire, August 3, 2011 | 08-03-2011 | |
| 374 | "PHAST Prescription," Symphony Health | | |
| 375 | Hoefle, "The Early History of Parke-Davis and Company", Bulletin for the History of Chemistry 25, No. 1 (2000) | 2000 | |
| 376 | Vasostriect Supplemental New Drug Application Approval Letter, Par Pharmaceutical Companies, Inc. | 12-16-2016 | |
| 377 | | | Par-0039661-Par-0039662 |
| 378 | American Regent website, Our Company, <www.americanregent.com> | | |
| 379 | Center for Drug Evaluation and Research Approval Package for Application Number: 204485Orig1s004, Vasostriect | 12-16-2016 | |
| 380 | "How did the Federal Food, Drug, and Cosmetic Act come about?" <www.fda.gov> | | |
| 381 | Symphony Health Integrated Pharmaceutical Audit Suite data | | |
| 382 | Truven Health Analytics Red Book Online Product Details: Pitressin, Vasostriect | | |
| 383 | List of materials Considered by Patterson | | |
| 384 | CV of Brian T. Wolfinger | | |
| 385 | List of Materials Considered by Brian T. Wolfinger | | |

| | | | |
|-----|--|------------|-------------------------|
| 386 | Chart titled: Thumb Drive Identification Chart | | |
| 387 | Photos taken by Brian T. Wolfinger of the Lenovo drive | | |
| 388 | Image log for the image provided of Ashley Short's hard drive | | |
| 389 | Image log for the image provided of Chinnasamay Subramaniam's hard drive | | |
| 390 | Image log for the image provided of Mike Rutkowski's hard drive | | |
| 391 | Screenshot provided from the forensic analysis conducted by Brian T. Wolfinger | | |
| 392 | Screenshot provided from the forensic analysis conducted by Brian T. Wolfinger, containing the title "Post Departure Disk Defragmentation: Screenshot of Software Analysis." | | |
| 393 | Lenovo Website, X1 Carbon 2 nd Gen (Type 20A7, 20A8) Laptop (ThinkPad) | | |
| 394 | Lenovo Magazine Website, How and When to Defragment Your Hard Drive in Windows 10 | | |
| 395 | Document titled "Defrag & Summary Data," prepared by Wolfinger Forensics | | |
| 396 | Screenshot provided from the forensic analysis conducted by Brian T. Wolfinger, containing the heading: Operating System Install Dates for Rutkowski and Subramaniam. | | |
| 397 | Custody Documents from Par | | Par-0040242-Par-0040253 |
| 398 | Screenshot provided from the forensic analysis conducted by Brian T. Wolfinger | | |
| 399 | Text message screenshots | | OMM-SC-0000047-53 |
| 400 | November 15, 2017 correspondence from Jenny Liu to DriveSavers | | OMM-SC-0000001 |
| 401 | Par Supplemental Responses to Interrogatories Nos. 1, 5, 8 and 9 | 10-30-2017 | |
| 402 | Bi et al., "HPLC Method for Quantification of Arginine Containing Vasopressin", J. Liq. Chrom. & Rel. Technol. 22(4):551-560 (1999) | 1999 | |
| 403 | Hermann et al., "Urinary excretion of angiotensin I, II, arginine vasopressin and oxytocin in patients with anaphylactoid reactions", Clinical and Experimental Allergy, 22:845-853 (1992) | 1992 | |
| 404 | Tsukakzaki et al, "Development of a High-Sensitivity Quantitation Method for Arginine Vasopressin by High-Performance Liquid Chromatography Tandem Mass Spectrometry, and Comparison with Quantitative Values by Radioimmunoassay", Analytical Sciences, 32:153-159 (February 2016). | 02-2016 | |
| 405 | Zhang et al. "Development and validation of a highly sensitive LC-MS/MS assay for the quantification of | 2014 | |

| | | | |
|-----|---|--------------|--|
| | arginine vasopressin in human plasma and urine: Application in preterm neonates and child”, J. Pharm. & Biomedical Analysis, 99:67-73 (2014) | | |
| 406 | CV of Mohan Rao | | |
| 407 | List of Materials Considered by Mohan Rao | | |
| 408 | Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug and Cosmetic Act, Guidance for Industry | January 2017 | |
| 409 | Transcript of September 29, 2017 hearing on expedited discovery | 09-30-2017 | |
| 410 | Declaration of Ahmed Soliman | 12-05-2017 | |
| 411 | Declaration of Angela Palomarez | 12-07-2017 | |
| 412 | Declaration of Ashley Short | 12-06-2017 | |
| 413 | Declaration of Chinnasamy Subramaniam | 12-05-2017 | |
| 414 | Declaration of David Michael Hartley | 12-07-2017 | |
| 415 | Declaration of David Short | 12-05-2017 | |
| 416 | Declaration of Donna Kohut | 12-04-2017 | |
| 417 | Declaration of Guy Thompson | 12-06-2017 | |
| 418 | Declaration of John B.White | 12-04-2017 | |
| 419 | Declaration of Mike Rutkowski | 12-06-2017 | |
| 420 | Declaration of Stephen Rhoades | 11-30-2017 | |
| 421 | Declaration of Stuart Hinch | 12-06-2017 | |
| 422 | Declaration of Travis Leeah | 12-06-2017 | |
| 423 | Declaration of Travis McGrady | 12-01-2017 | |
| 424 | Declaration of Harold Patterson | | |
| 425 | Declaration of Dr. Rodolfo Pinal | | |
| 426 | Declaration of Brian T. Wolfinger | 12-07-2017 | |
| 427 | Declaration of Dr. Mohan P. Rao | | |